Related Experiment Video
Updated: Aug 17, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions
D W Muller1, S G Ellis, E J Topol
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0022.
Abstract:
The complexity of the events that culminate in intimal proliferation after arterial injury and similarities between this response and benign neoplasia suggest that conventional medical therapies will continue to be unsuccessful in preventing recurrent stenosis after percutaneous coronary revascularization. By preventing cell division after smooth muscle cell activation, antimitogenic therapy may inhibit the final common pathway in this complex chain of events and offset the apparent loss of local growth control. Colchicine, which causes metaphase arrest of cell division, has been shown in experimental studies to decrease the extent of atheromatous plaque formation and reduce the severity of arterial restenosis after balloon angioplasty. However, preliminary results from a randomized placebo-controlled clinical trial suggest that low dose colchicine (0.6 mg twice a day orally) does not prevent restenosis. The use of more potent antineoplastic agents is limited by the potential for life-threatening side effects. It is possible that these adverse effects can be averted by using novel drug delivery systems to administer antimitogenic therapy locally at the site of arterial injury or by using low dose synergistic combinations of antiproliferative agents. This review examines the potential role of antimitogenic therapy in the prevention of restenosis after coronary interventions and considers the possibility of an overlap of the therapeutic realms of interventional cardiology and medical oncology.
Insights
Antimitogenic therapy aims to prevent restenosis after coronary interventions by inhibiting cell division. However, low-dose colchicine trials show limited success, suggesting novel approaches are needed for effective treatment.
Area of Science:
- Cardiovascular Science
- Medical Oncology
- Pharmacology
Background:
- Arterial injury triggers intimal proliferation, similar to benign neoplasia, leading to recurrent stenosis after percutaneous coronary revascularization.
- Conventional therapies often fail to prevent this restenosis, highlighting the need for novel treatment strategies.
- Antimitogenic therapy, by inhibiting cell division, offers a potential pathway to control smooth muscle cell proliferation.
Purpose of the Study:
- To review the potential role of antimitogenic therapy in preventing restenosis after coronary interventions.
- To explore novel drug delivery systems and combination therapies to overcome limitations of current antimitogenic treatments.
- To consider the intersection of interventional cardiology and medical oncology in managing post-intervention restenosis.
Main Methods:
- Review of experimental studies on colchicine's effect on atheromatous plaque and arterial restenosis.
- Analysis of preliminary results from a randomized placebo-controlled clinical trial of low-dose colchicine.
- Discussion of potential strategies including local drug delivery and synergistic combinations of antiproliferative agents.
Main Results:
- Experimental studies suggest colchicine can reduce atheromatous plaque and restenosis severity.
- Preliminary clinical trial data indicate low-dose colchicine (0.6 mg twice daily) does not prevent restenosis.
- Potent antineoplastic agents are limited by severe side effects, necessitating alternative approaches.
Conclusions:
- Antimitogenic therapy holds promise for preventing restenosis, but current approaches face challenges.
- Novel drug delivery systems or low-dose synergistic combinations may overcome limitations of existing antimitogenic agents.
- Future strategies may involve integrating interventional cardiology and medical oncology principles for improved patient outcomes.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care